DexCom, Inc. (DXCM) 2024 10-K Earnings Analysis
DexCom, Inc.2024 Earnings Analysis
75/100
DexCom, Inc.'s FY2024 10-K for the period ended December 31, 2024 is easiest to read through $4.03B of revenue, $576M of net income, and $631M of free cash flow. G7 CGM Platform, Stelo OTC CGM, and CGM Sensor Position remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Gross margin was 60.5% and operating margin was 14.9%, with G7 CGM Platform still doing the economic work, so FY2024 does not look like a year bought with weak pricing or loose cost control. The next test is whether Type-2 Penetration Cadence and US Pricing Pressure stay manageable without compromising returns.
Filing analysis
DexCom, Inc. 2024 10-K Analysis
This page reads DexCom, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 75/100, or grade C.
DXCM Earnings Quality
The earnings-quality module scores 75/100, with Gross Margin: 60.5%, Operating Margin: 14.9%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
DXCM Economic Moat Analysis
The moat-strength module scores 80/100, with CGM Sensor Position: Type-1 leader / Type-2 expansion, Pump Integration: Tandem/Insulet partnerships. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
DXCM Free Cash Flow vs Net Income
CF/Net Income: 1.72x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
DXCM Key Risks from the Annual Report
The risk module scores 68/100, with Abbott Libre Competition: Strong Type-2 position, Type-2 Penetration Cadence: Reimbursement-dependent. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is DXCM a High Quality Earnings Stock?
Based on this 2024 filing, DXCM needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 75/100. This is a research screen, not investment advice.
Read the report first
Understand DexCom, Inc. first, then decide if it belongs on your watchlist
The DXCM score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep DXCM with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the DXCM report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross Margin is worth reading alongside the rest of the file because gross Margin is worth reading alongside the rest of the file because gross margin of 60.5% reflects the disclosed CGM-sensor product mix.
On operating margin, the useful point is that on operating margin, the useful point is that the 14.9% operating margin reflects the disclosed SG&A reinvestment cadence (commercial-team scale-up as described in the strategic-investment communications).
CF / Net Income matters here because CF / Net Income matters here because OCF of $990M is 1.72x net income of $576M — reflecting depreciation on sensor-manufacturing capacity per the property and equipment footnote.
FY2024 10-K shows $576M of net income on $4.03B of revenue, but the cleaner read is the $990M of operating cash flow that turned into $631M of free cash flow. G7 CGM Platform and Stelo OTC CGM help explain why the margin profile stayed where it did instead of collapsing with every demand wobble. Operating margin landed at 14.9%, while G7 CGM Platform absorbed capex running at 8.9% of revenue. Cash is moving cleanly through G7 CGM Platform and Stelo OTC CGM, which reduces the odds that FY2024 earnings are being flattered by accruals.
Moat Strength
CGM Sensor Position matters because CGM Sensor Position matters because dexCom holds a leading share of the Type-1 diabetes CGM market per public industry-analyst coverage and is expanding into the Type-2 / non insulin using diabetes population as described in the Stelo OTC-CGM launch.
What pump integration really tells you is that what pump integration really tells you is that insulet Omnipod 5 as described in the partnership communications) — creating clinical workflow integration.
The practical value of g7 platform is that the practical value of g7 platform is that the G7 next-generation CGM sensor (smaller form factor with simplified application as described in the product launch) is the current-generation device.
The competitive position starts with G7 CGM Platform and Stelo OTC CGM, not with a vague appeal to scale. CGM Sensor Position and G7 Platform matter because they deepen switching friction, expand installed-base economics, or widen route to market reach. FY2024 ROE was 27.4%, but the more important check is that G7 CGM Platform still turns operating advantages into cash and margin support. That does not make the business immune; it means a competitor still has to overcome G7 CGM Platform and a functioning operating system rather than just a familiar name.
Capital Allocation
Free Cash Flow is relevant because free Cash Flow is relevant because FCF of $631M (OCF $990M minus capex $359M) reflects continued sensor manufacturing capacity investment per the property and equipment footnote.
On capex investment, the file suggests that on capex investment, the file suggests that capex of $359M on $4.03B revenue equals 9% — elevated, reflecting sensor manufacturing capacity build-out for G7 ramp and Stelo launch as described in the capacity-expansion communications.
No Dividend tells you that no Dividend tells you that dexCom does not pay a dividend; cash generation is reinvested into manufacturing capacity and commercial expansion.
$631M of free cash flow is the starting point for the capital-allocation discussion, because it defines how much room management actually had after funding G7 CGM Platform and the broader business. Capex at 8.9% of revenue is meaningful but still leaves plenty of room for management to direct cash elsewhere. $606M of cash gives management flexibility, and the filing does not make leverage the defining issue of FY2024. The dividend remains the primary recurring commitment, which makes payout coverage more important than headline EPS.
Key Risks
Abbott Libre Competition belongs on the watch list because abbott Libre Competition belongs on the watch list because abbott's FreeStyle Libre CGM family (with Libre Rio OTC launch per public Abbott communications) competes principally in the Type 2 diabetes CGM segment.
The point of type-2 penetration cadence is that the point of type-2 penetration cadence is that type 2 diabetes CGM penetration cadence depends on reimbursement-policy expansion as described in the payer-coverage communications and the OTC Stelo cash-pay channel.
US Pricing Pressure matters as a risk because US Pricing Pressure matters as a risk because channel-mix shifts toward pharmacy benefit (versus DME) and competitive-pricing dynamics as described in the payer-arrangement communications.
The risk section is better read through Type-2 Penetration Cadence and US Pricing Pressure than as one binary red flag. Type-2 Penetration Cadence can travel into margins and cash conversion faster than the headline score suggests once US Pricing Pressure starts building. Balance-sheet risk is manageable on paper, so most of the real watch items still sit in Type-2 Penetration Cadence, mix, and demand rather than in accounting optics. The next test is whether Type-2 Penetration Cadence and US Pricing Pressure stay manageable without compromising returns.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.